News
FDA Suspends U.S. License of Chikungunya Vaccine
By Stephanie Brown HealthDay ReporterMONDAY, Aug. 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports of serious side effects in older adults similar to the symptoms of chikungunya virus.
The recalls have been classified as Class II, where the probability of serious adverse health consequences is remote.
Although VIZZ is, so far, the first and only FDA-approved aceclidine eye drop, it’s one of three prescription eye drops ...
Verywell Health on MSN14h
Wegovy Is Now the Second FDA-Approved Treatment for MASH Fibrosis
Drugmaker Novo Nordisk received accelerated approval for the drug’s use in people with moderate to advanced liver scarring, ...
The Food and Drug Administration approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent ...
FDA delays Axogen's Avance Nerve Graft BLA review to December 5, after new data submission, while the company raises its full ...
The Food and Drug Administration has issued warning letters to several companies producing whipped formulas of sunscreen.
KOIN Portland on MSN8h
Washington, Oregon join states urging FDA to lift restrictions on abortion pill
Petitioners have claimed the FDA hasn’t enforced “extra and unnecessary requirements” for many of the other drugs it ...
SCA slowdown, with FDA review set for Q4 2025 and no advisory meeting required. Find out why BHVN stock is a strong buy.
The FDA has begun publishing reports of adverse events concerning drugs and biological products on a daily basis ...
HHS announced Aug. 22 it plans to decertify union representation in several agencies, which would affect thousands of agency employees, according to the American Federation of Government Employees. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback